IDEXX Laboratories Inc (IDXX, Financial) is set to release its Q2 2024 earnings on Aug 6, 2024. The consensus estimate for Q2 2024 revenue is $1.01 billion, and the earnings are expected to come in at $2.89 per share. The full year 2024's revenue is expected to be $3.94 billion and the earnings are expected to be $11.05 per share. More detailed estimate data can be found on the Estimates page.
IDEXX Laboratories Inc (IDXX, Financial) Estimates Trends
Over the past 90 days, revenue estimates for IDEXX Laboratories Inc (IDXX) have seen a downward revision, moving from $3.95 billion to $3.94 billion for the full year 2024, and from $4.34 billion to $4.31 billion for 2025. Conversely, earnings estimates have shown a slight increase from $11.02 per share to $11.05 per share for the full year 2024, while remaining steady at $12.48 per share for 2025.
IDEXX Laboratories Inc (IDXX, Financial) Reported History
In the previous quarter of March 31, 2024, IDEXX Laboratories Inc's (IDXX) actual revenue was $964.10 million, which missed analysts' revenue expectations of $966.13 million by -0.21%. IDEXX Laboratories Inc's (IDXX) actual earnings were $2.81 per share, which beat analysts' earnings expectations of $2.67 per share by 5.28%. After releasing the results, IDEXX Laboratories Inc (IDXX) was down by -5.02% in one day.
IDEXX Laboratories Inc (IDXX, Financial) 12 Month Price Targets
Based on the one-year price targets offered by 11 analysts, the average target price for IDEXX Laboratories Inc (IDXX) is $558.67 with a high estimate of $641 and a low estimate of $470. The average target implies an upside of 19.15% from the current price of $468.89.
Based on GuruFocus estimates, the estimated GF Value for IDEXX Laboratories Inc (IDXX, Financial) in one year is $611.71, suggesting an upside of 30.46% from the current price of $468.89.
Based on the consensus recommendation from 14 brokerage firms, IDEXX Laboratories Inc's (IDXX, Financial) average brokerage recommendation is currently 2.4, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
